{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:28:43Z","timestamp":1784834923957,"version":"3.55.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dahdaleh Institute for Global Health Research"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Substance Use and Addiction Program, Health Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01409-x","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:57:42Z","timestamp":1770368262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cWith this you\u2019re not chained down to something\u201d: contrasting experiences of opioid agonist treatment and safer supply program participation among people receiving prescribed safer supply"],"prefix":"10.1186","volume":"23","author":[{"given":"Liam","family":"Michaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Guta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Schaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourteney","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Strike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"1409_CR1","unstructured":"Public Health Agency of Canada. Key findings: Opioid- and Stimulant-related Harms in Canada \u2014 Canada.ca [Internet]. 2025 [cited 2025 Apr 5]. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"1409_CR2","unstructured":"Canadian Association of People who Use Drugs. Safe Supply Concept Doc. 2019;16."},{"issue":"12","key":"1409_CR3","doi-asserted-by":"publisher","first-page":"e0315804","DOI":"10.1371\/journal.pone.0315804","volume":"19","author":"J Bowles","year":"2024","unstructured":"Bowles J, Nyx E, Kalicum J, Kerr T. Qualitative findings from North america\u2019s first drug compassion club. PLoS ONE. 2024;19(12):e0315804.","journal-title":"PLoS ONE"},{"key":"1409_CR4","doi-asserted-by":"crossref","unstructured":"Kalicum J, Nyx E, Kennedy MC, Kerr T. The impact of an unsanctioned compassion club on non-fatal overdose. Int J Drug Policy. 2024;104330.","DOI":"10.1016\/j.drugpo.2024.104330"},{"key":"1409_CR5","doi-asserted-by":"publisher","unstructured":"Schmidt RA, Guta A, Rai N, Sereda A, O\u2019Reilly E, Hales J et al. Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis. Can J Public Health. 2024. https:\/\/doi.org\/10.17269\/s41997-024-00979-2","DOI":"10.17269\/s41997-024-00979-2"},{"key":"1409_CR6","doi-asserted-by":"publisher","first-page":"103742","DOI":"10.1016\/j.drugpo.2022.103742","volume":"106","author":"S Glegg","year":"2022","unstructured":"Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. COVID just kind of opened a can of whoop-ass: the rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int J Drug Policy. 2022;106:103742.","journal-title":"Int J Drug Policy"},{"key":"1409_CR7","doi-asserted-by":"publisher","first-page":"104157","DOI":"10.1016\/j.drugpo.2023.104157","volume":"120","author":"M Karamouzian","year":"2023","unstructured":"Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis. Int J Drug Policy. 2023;120:104157.","journal-title":"Int J Drug Policy"},{"key":"1409_CR8","unstructured":"Hales, Kolla G, Man T, O\u2019Reilly E, Rai N, Serada A. Safer Opioid Supply Programs (S)S): A harm reduction informed guiding document for primary care teams - April 2020 update [Internet]. 2019 [cited 2023 Jan 24]. Available from: https:\/\/docs.google.com\/document\/d\/e\/2PACX-1vTMQEhchBfmTjeBxpDRi6w7pXE5EDuInMiKARuxBcxvFUtjPmqk8l7AFPGYvWn3hOHWkTMo8-m5QPI0\/pub"},{"key":"1409_CR9","doi-asserted-by":"crossref","unstructured":"Gomes T, Kolla G, McCormack D, Sereda A, Kitchen S, Antoniou T. Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario. CMAJ 2022 Sept 19;194(36):E1233\u201342.","DOI":"10.1503\/cmaj.220892"},{"key":"1409_CR10","doi-asserted-by":"publisher","first-page":"103601","DOI":"10.1016\/j.drugpo.2022.103601","volume":"102","author":"S Young","year":"2022","unstructured":"Young S, Kolla G, McCormack D, Campbell T, Leece P, Strike C, et al. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. Int J Drug Policy. 2022;102:103601.","journal-title":"Int J Drug Policy"},{"key":"1409_CR11","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-025-01006-8","volume-title":"Comprehensive substance use services within primary care settings","author":"K Fajber","year":"2025","unstructured":"Fajber K, Sereda A, Warren S, Morris C, Nash G, Pauly B, et al. Comprehensive substance use services within primary care settings. The Safer Opioid Supply program at London InterCommunity Health Centre; 2025. https:\/\/doi.org\/10.17269\/s41997-025-01006-8"},{"key":"1409_CR12","doi-asserted-by":"publisher","unstructured":"Schmidt RA, Guta A, Rai N, Sereda A, O\u2019Reilly E, Hales J et al. Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis. Can J Public Health. https:\/\/doi.org\/10.17269\/s41997-024-00979-2","DOI":"10.17269\/s41997-024-00979-2"},{"key":"1409_CR13","doi-asserted-by":"publisher","unstructured":"Schmidt RA, Kaminski N, Kryszajtys DT, Rudzinski K, Perri M, Guta A et al. \u2018I don\u2019t chase drugs as much anymore, and I\u2019m not dead\u2019: Client reported outcomes associated with safer opioid supply programs in Ontario, Canada. Drug Alcohol Rev [Internet]. 2023 [cited 2023 Sept 25];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/dar.13745","DOI":"10.1111\/dar.13745"},{"key":"1409_CR14","unstructured":"BC Centre on Substance Use. Risk Mitigation In the Context of Dual Public Health Emergencies [Internet]. 2022. Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/02\/Risk-Mitigation-Guidance-Update-February-2022.pdf"},{"key":"1409_CR15","unstructured":"Canada H. Safer supply: Prescribed medications as a safer alternative to toxic illegal drugs [Internet]. 2021 [cited 2025 July 7]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply.html"},{"key":"1409_CR16","doi-asserted-by":"crossref","unstructured":"Socias ME, CHOI JC, FAIRBAIRN N, JOHNSON C, WILSON D, DEBECK K et al. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, canada: an interrupted time series analysis. Int J Drug Policy. 2023;104075.","DOI":"10.1016\/j.drugpo.2023.104075"},{"key":"1409_CR17","doi-asserted-by":"crossref","unstructured":"Pauly B, Kurz M, Dale LM, Macevicius C, Kalicum J, P\u00e9rez DG et al. Implementation of pharmaceutical alternatives to a toxic drug supply in British columbia: A mixed methods study. J Subst Use Addict Treat. 2024;209341.","DOI":"10.1016\/j.josat.2024.209341"},{"key":"1409_CR18","doi-asserted-by":"publisher","first-page":"109440","DOI":"10.1016\/j.drugalcdep.2022.109440","volume":"235","author":"TD Brothers","year":"2022","unstructured":"Brothers TD, Leaman M, Bonn M, Lewer D, Atkinson J, Fraser J, et al. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022;235:109440.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1409_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-022-00614-8","volume":"19","author":"B Lew","year":"2022","unstructured":"Lew B, Bodkin C, Lennox R, O\u2019Shea T, Wiwcharuk G, Turner S. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct J. 2022;19(1):29.","journal-title":"Harm Reduct J"},{"key":"1409_CR20","doi-asserted-by":"crossref","unstructured":"Kolla G, Pauly B, Cameron F, Hobbs H, McCall J, Majalahti J et al. If it wasn\u2019t for them, I don\u2019t think I would be here: experiences of the first year of a safer supply program during the dual public health emergencies of COVID and the drug toxicity crisis. 2024.","DOI":"10.1186\/s12954-024-01029-3"},{"key":"1409_CR21","doi-asserted-by":"publisher","first-page":"104339","DOI":"10.1016\/j.drugpo.2024.104339","volume":"125","author":"S Ledlie","year":"2024","unstructured":"Ledlie S, Garg R, Cheng C, Kolla G, Antoniou T, Bouck Z, et al. Prescribed safer opioid supply: A scoping review of the evidence. Int J Drug Policy. 2024;125:104339.","journal-title":"Int J Drug Policy"},{"key":"1409_CR22","doi-asserted-by":"publisher","unstructured":"Nafeh F, Mbichila T, Bouck Z, Scheim A, Mitra S, Bonn M et al. A Preliminary Assessment of Short-Term Social and Substance Use-Related Outcomes Among Clients of Integrated Safer Opioid Supply Pilot Programs in Toronto, Canada. Int J Ment Health Addict. 2023. https:\/\/doi.org\/10.1007\/s11469-023-01219-3","DOI":"10.1007\/s11469-023-01219-3"},{"key":"1409_CR23","doi-asserted-by":"crossref","unstructured":"Slaunwhite A, Min JE, Palis H, Urbanoski K, Pauly B, Barker B et al. Effect of risk mitigation guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. BMJ. 2024;e076336.","DOI":"10.1136\/bmj-2023-076336"},{"issue":"12","key":"1409_CR24","doi-asserted-by":"publisher","first-page":"e0295145","DOI":"10.1371\/journal.pone.0295145","volume":"18","author":"S Young","year":"2023","unstructured":"Young S, Gomes T, Kolla G, McCormack D, Dodd Z, Raboud J, et al. Initiations of safer supply hydromorphone increased during the COVID-19 pandemic in ontario: an interrupted time series analysis. PLoS ONE. 2023;18(12):e0295145.","journal-title":"PLoS ONE"},{"issue":"5","key":"1409_CR25","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/S2468-2667(25)00070-2","volume":"10","author":"T Gomes","year":"2025","unstructured":"Gomes T, McCormack D, Kolla G, Young S, Bayoumi AM, Smoke A, et al. Comparing the effects of prescribed safer opioid supply and methadone in Ontario, canada: a population-based matched cohort study. Lancet Public Health. 2025;10(5):e412\u201321.","journal-title":"Lancet Public Health"},{"key":"1409_CR26","doi-asserted-by":"crossref","unstructured":"Kolla G, Fajber K, Sereda A, Morris C, Deacon P, Cipriano LE. Opioid medication doses among safer supply clients: current safer supply doses and previous OAT experience. Drug Alcohol Depend Rep. 2025;100338.","DOI":"10.1016\/j.dadr.2025.100338"},{"issue":"4","key":"1409_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/add.16096","volume":"118","author":"LA Paul","year":"2023","unstructured":"Paul LA, Bayoumi AM, Chen C, Kocovska E, Smith BT, Raboud JM, et al. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study. Addiction. 2023;118(4):686\u201397.","journal-title":"Addiction"},{"key":"1409_CR28","doi-asserted-by":"publisher","first-page":"104423","DOI":"10.1016\/j.drugpo.2024.104423","volume":"127","author":"L Michaud","year":"2024","unstructured":"Michaud L, Kolla G, Rudzinski K, Guta A. Mapping a moral panic: news media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada. Int J Drug Policy. 2024;127:104423.","journal-title":"Int J Drug Policy"},{"key":"1409_CR29","doi-asserted-by":"publisher","first-page":"104537","DOI":"10.1016\/j.drugpo.2024.104537","volume":"131","author":"E Nyx","year":"2024","unstructured":"Nyx E, Kalicum J. A case study of the DULF compassion club and fulfillment centre\u2014A logical step forward in harm reduction. Int J Drug Policy. 2024;131:104537.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"1409_CR30","doi-asserted-by":"publisher","first-page":"e2451988","DOI":"10.1001\/jamanetworkopen.2024.51988","volume":"7","author":"M Olding","year":"2024","unstructured":"Olding M, Rudzinski K, Schmidt R, Kolla G, German D, Sereda A, et al. Perspectives on diversion of medications from safer opioid supply programs. JAMA Netw Open. 2024;7(12):e2451988.","journal-title":"JAMA Netw Open"},{"key":"1409_CR31","doi-asserted-by":"publisher","first-page":"104731","DOI":"10.1016\/j.drugpo.2025.104731","volume":"137","author":"M Haines","year":"2025","unstructured":"Haines M, Hill E, O\u2019Byrne P. Safer supply programs: discussions on medication diversion, sharing, and selling. Int J Drug Policy. 2025;137:104731.","journal-title":"Int J Drug Policy"},{"key":"1409_CR32","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.drugpo.2024.104665","volume":"135","author":"L Martignetti","year":"2025","unstructured":"Martignetti L, Knight R, Nafeh F, Atkinson K, Laurence G, Johnson CH, et al. Motivations for and perspectives of medication diversion among clients of a safer opioid supply program in Toronto, Canada. Int J Drug Policy. 2025;135:104665.","journal-title":"Int J Drug Policy"},{"key":"1409_CR33","doi-asserted-by":"publisher","first-page":"113986","DOI":"10.1016\/j.socscimed.2021.113986","volume":"279","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Small W, Lavalley J, McNeil R, Kerr T. People need them or else they\u2019re going to take Fentanyl and die: A qualitative study examining the \u2018problem\u2019 of prescription opioid diversion during an overdose epidemic. Soc Sci Med. 2021;279:113986.","journal-title":"Soc Sci Med"},{"key":"1409_CR34","doi-asserted-by":"publisher","first-page":"109109","DOI":"10.1016\/j.drugalcdep.2021.109109","volume":"228","author":"ME Socias","year":"2021","unstructured":"Socias ME, Grant C, Hayashi K, Bardwell G, Kennedy MC, Milloy MJ, et al. The use of diverted pharmaceutical opioids is associated with reduced risk of Fentanyl exposure among people using unregulated drugs in Vancouver, Canada. Drug Alcohol Depend. 2021;228:109109.","journal-title":"Drug Alcohol Depend"},{"key":"1409_CR35","doi-asserted-by":"publisher","first-page":"104600","DOI":"10.1016\/j.drugpo.2024.104600","volume":"133","author":"P Wilson","year":"2024","unstructured":"Wilson P, Colizza K, Hyshka E. Safer supply and political interference in medical practice: alberta\u2019s narcotics transition services. Int J Drug Policy. 2024;133:104600.","journal-title":"Int J Drug Policy"},{"key":"1409_CR36","unstructured":"DeRosa K. B.C. ends take-home safer supply for drug users to stop diversion. CBC News [Internet]. 2025 Feb 19 [cited 2025 July 7]; Available from: https:\/\/www.cbc.ca\/news\/canada\/british-columbia\/take-home-supply-drug-ending-1.7463197"},{"key":"1409_CR37","unstructured":"The Tyee [Internet]. [cited 2025 July 7]. BC Restricts Safer Supply, Promises Pharmacy Crackdown. Available from: https:\/\/thetyee.ca\/News\/2025\/02\/21\/BC-Restricts-Safer-Supply-Pharmacy-Crackdown\/"},{"key":"1409_CR38","unstructured":"Government of Ontario. news.ontario.ca. 2024 [cited 2025 Apr 5]. Ontario Protecting Communities and Supporting Addiction Recovery with New Treatment Hubs. Available from: https:\/\/news.ontario.ca\/en\/release\/1004955\/ontario-protecting-communities-and-supporting-addiction-recovery-with-new-treatment-hubs"},{"key":"1409_CR39","unstructured":"Government of B.C. BC Gov News. 2025 [cited 2025 Apr 5]. Government provides update on pharmacy investigations, prescribed alternatives. Available from: https:\/\/news.gov.bc.ca\/releases\/2025HLTH0008-000127"},{"key":"1409_CR40","doi-asserted-by":"publisher","first-page":"103849","DOI":"10.1016\/j.drugpo.2022.103849","volume":"110","author":"B Pauly","year":"2022","unstructured":"Pauly B, McCall J, Cameron F, Stuart H, Hobbs H, Sullivan G, et al. A concept mapping study of service user design of safer supply as an alternative to the illicit drug market. Int J Drug Policy. 2022;110:103849.","journal-title":"Int J Drug Policy"},{"issue":"38","key":"1409_CR41","doi-asserted-by":"publisher","first-page":"E1280","DOI":"10.1503\/cmaj.241173","volume":"196","author":"I Yakovenko","year":"2024","unstructured":"Yakovenko I, Mukaneza Y, Germ\u00e9 K, Belliveau J, Fraleigh R, Bach P, et al. Management of opioid use disorder: 2024 update to the National clinical practice guideline. CMAJ. 2024;196(38):E1280\u201390.","journal-title":"CMAJ"},{"key":"1409_CR42","unstructured":"Bromley L, Kahan M, Regenstreif L, Srivastava A, Wyman J, Dabam F. Methadone treatment for people who use fentanyl: Recommendations [Internet]. Toronto, ON: META: PHI; 2021. Available from: https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_MethadoneForFentanyl.pdf"},{"key":"1409_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2016.07.006","volume":"69","author":"J Teoh Bing Fei","year":"2016","unstructured":"Teoh Bing Fei J, Yee A, Habil MHB, Danaee M. Effectiveness of methadone maintenance therapy and improvement in quality of life following a decade of implementation. J Subst Abuse Treat. 2016;69:50\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"1409_CR44","doi-asserted-by":"publisher","first-page":"e2344528","DOI":"10.1001\/jamanetworkopen.2023.44528","volume":"6","author":"K Corace","year":"2023","unstructured":"Corace K, Thavorn K, Suschinsky K, Willows M, Leece P, Kahan M, et al. Rapid access addiction medicine clinics for people with problematic opioid use. JAMA Netw Open. 2023;6(11):e2344528.","journal-title":"JAMA Netw Open"},{"key":"1409_CR45","doi-asserted-by":"publisher","first-page":"112451","DOI":"10.1016\/j.drugalcdep.2024.112451","volume":"264","author":"P Boilard","year":"2024","unstructured":"Boilard P, Wang T, Iacono A, Ghosh SM, Gomes T. Trends in injectable buprenorphine prescribing in canada: A descriptive analysis in five Canadian provinces. Drug Alcohol Depend. 2024;264:112451.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1409_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13011-019-0250-1","volume":"15","author":"D Wiercigroch","year":"2020","unstructured":"Wiercigroch D, Sheikh H, Hulme J. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Subst Abuse Treat Prev Policy. 2020;15(1):4.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1409_CR47","doi-asserted-by":"crossref","unstructured":"Frank D. Methadone maintenance treatment is swapping one drug for another, and that\u2019s why it works: towards a treatment-based critique of the war on drugs. Int J Drug Policy. 2020 Sept;83:102844.","DOI":"10.1016\/j.drugpo.2020.102844"},{"issue":"2","key":"1409_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/10826084.2017.1310247","volume":"53","author":"D Frank","year":"2018","unstructured":"Frank D. I was not sick and I didn\u2019t need to recover: methadone maintenance treatment (MMT) as a refuge from criminalization. Subst Use Misuse. 2018;53(2):311\u201322.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"1409_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2307\/3343343","volume":"21","author":"B Fischer","year":"2000","unstructured":"Fischer B, Prescriptions. Power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. 2000;21(2):187\u2013210.","journal-title":"J Public Health Policy"},{"key":"1409_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.drugalcdep.2017.05.002","volume":"177","author":"Q Guan","year":"2017","unstructured":"Guan Q, Khuu W, Spithoff S, Kiran T, Kahan M, Tadrous M, et al. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. Drug Alcohol Depend. 2017;177:315\u201321.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1409_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/ADM.0000000000000950","volume":"16","author":"RA Kleinman","year":"2022","unstructured":"Kleinman RA, Brothers TD, Danilewitz M, Bahji A. Office-based methadone prescribing for opioid use disorder: the Canadian model. J Addict Med. 2022;16(5):499.","journal-title":"J Addict Med"},{"issue":"2","key":"1409_CR52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","volume":"108","author":"N Dasgupta","year":"2018","unstructured":"Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health 1971. 2018;108(2):182\u20136.","journal-title":"Am J Public Health 1971"},{"key":"1409_CR53","doi-asserted-by":"crossref","unstructured":"Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the united States. Cult Med Psychiatry. 2000 June;24(2):165\u201395.","DOI":"10.1023\/A:1005574918294"},{"issue":"6","key":"1409_CR54","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.drugpo.2013.07.004","volume":"24","author":"S Crawford","year":"2013","unstructured":"Crawford S. Shouting through bullet-proof glass: some reflections on pharmacotherapy provision in one Australian clinic. Int J Drug Policy. 2013;24(6):e14\u20137.","journal-title":"Int J Drug Policy"},{"key":"1409_CR55","doi-asserted-by":"crossref","unstructured":"Ling W. A perspective on opioid pharmacotherapy: where we are and how we got here. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2016 Sept;11(3):394\u2013400.","DOI":"10.1007\/s11481-016-9663-z"},{"key":"1409_CR56","doi-asserted-by":"crossref","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. It\u2019s like \u2018liquid handcuffs: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18.","DOI":"10.1186\/s12954-021-00535-y"},{"key":"1409_CR57","unstructured":"Vanderkloot P, National Harm Reduction C. 2001 [cited 2025 Apr 5]. Methadone: Medicine, harm reduction or social control. Available from: https:\/\/issuu.com\/harmreduction\/docs\/hrc_2001_spring"},{"key":"1409_CR58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugpo.2018.08.006","volume":"64","author":"J McEachern","year":"2019","unstructured":"McEachern J, Adye-White L, Priest KC, Moss E, Gorfinkel L, Wood E, et al. Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy. Int J Drug Policy. 2019;64:30\u20133.","journal-title":"Int J Drug Policy"},{"key":"1409_CR59","doi-asserted-by":"publisher","first-page":"108155","DOI":"10.1016\/j.jsat.2020.108155","volume":"120","author":"JD Pytell","year":"2021","unstructured":"Pytell JD, Rastegar DA. Down the drain: reconsidering routine urine drug testing during the COVID-19 pandemic. J Subst Abuse Treat. 2021;120:108155.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"1409_CR60","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/14659890903431603","volume":"15","author":"C Strike","year":"2010","unstructured":"Strike C, Rufo C. Embarrassing, degrading, or beneficial: patient and staff perspectives on urine drug testing in methadone maintenance treatment. J Subst Use. 2010;15(5):303\u201312.","journal-title":"J Subst Use"},{"issue":"6","key":"1409_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugpo.2013.04.010","volume":"24","author":"C Treloar","year":"2013","unstructured":"Treloar C. valentine kylie. Examining structural violence in opioid pharmacotherapy treatment in Australia: Sweating the small stuff in a liberal paradise. Int J Drug Policy. 2013;24(6):11\u20133.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1409_CR62","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","volume":"9","author":"JK Eibl","year":"2015","unstructured":"Eibl JK, Gomes T, Martins D, Camacho X, Juurlink DN, Mamdani MM, et al. Evaluating the effectiveness of First-Time methadone maintenance therapy across Northern, Rural, and urban regions of Ontario, Canada. J Addict Med. 2015;9(6):440\u20136.","journal-title":"J Addict Med"},{"issue":"2","key":"1409_CR63","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/10826084.2017.1342662","volume":"53","author":"K McElrath","year":"2018","unstructured":"McElrath K. Medication-Assisted treatment for opioid addiction in the united states: critique and commentary. Subst Use Misuse. 2018;53(2):334\u201343.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"1409_CR64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/dar.13049","volume":"39","author":"R McNeil","year":"2020","unstructured":"McNeil R, Puri N, Boyd J, Mayer S, Hayashi K, Small W. Understanding concurrent stimulant use among people on methadone: A qualitative study. Drug Alcohol Rev. 2020;39(3):209\u201315.","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"1409_CR65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.15288\/jsad.2020.81.405","volume":"81","author":"H Rosenberg","year":"2020","unstructured":"Rosenberg H, Grant J, Davis AK. Acceptance of Non-Abstinence as an outcome goal for individuals diagnosed with substance use disorders: A narrative review of published research. J Stud Alcohol Drugs. 2020;81(4):405\u201315.","journal-title":"J Stud Alcohol Drugs"},{"key":"1409_CR66","doi-asserted-by":"publisher","first-page":"104075","DOI":"10.1016\/j.drugpo.2023.104075","volume":"118","author":"ME Socias","year":"2023","unstructured":"Socias ME, Choi JC, Fairbairn N, Johnson C, Wilson D, Debeck K, et al. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, canada: an interrupted time series analysis. Int J Drug Policy. 2023;118:104075.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1409_CR67","doi-asserted-by":"publisher","first-page":"e2411389","DOI":"10.1001\/jamanetworkopen.2024.11389","volume":"7","author":"JE Min","year":"2024","unstructured":"Min JE, Guerra-Alejos BC, Yan R, Palis H, Barker B, Urbanoski K, et al. Opioid coprescription through risk mitigation guidance and opioid agonist treatment receipt. JAMA Netw Open. 2024;7(5):e2411389.","journal-title":"JAMA Netw Open"},{"key":"1409_CR68","unstructured":"Perri M, Fajber, Kaitlin, Guta, Adrian, Strike C, Kolla G. The Kitchener-Waterloo Safer Supply Program: A Collaborative Model of Care: Report 2. [Internet]. 2023 Aug. Available from: https:\/\/www.nss-aps.ca\/sites\/default\/files\/resources\/2023-KWSaferSupplyReport2.pdf"},{"key":"1409_CR69","unstructured":"Perri M, Fajber K, Guta A, Strike C, Kolla G. Outcomes from the Safer Supply Program in Kitchener-Waterloo: Report 1. [Internet]. 2023 Aug. Available from: https:\/\/www.nss-aps.ca\/sites\/default\/files\/resources\/2023-KWSaferSupplyReport1.pdf"},{"issue":"1","key":"1409_CR70","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12954-025-01344-3","volume":"22","author":"C Strike","year":"2025","unstructured":"Strike C, Rudzinski K, Schmidt RA, Kolla G, Kryszajits D, Perri M, et al. A sea of need: provider accounts of strategies used to manage admission demands to safer opioid supply programs in Ontario. Harm Reduct J. 2025;22(1):194.","journal-title":"Harm Reduct J"},{"key":"1409_CR71","unstructured":"Gomes T, McCormack D, Kolla G, Young S, Bayoumi AM, Smoke A et al. Comparing the effects of prescribed safer opioid supply and methadone in Ontario, Canada: a population-based matched cohort study. Lancet Public Health [Internet]. 2025 Apr 22 [cited 2025 Apr 26];0(0). Available from: https:\/\/www.thelancet.com\/journals\/lanpub\/article\/PIIS2468-2667(25)00070-2\/fulltext"},{"key":"1409_CR72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1037\/13620-004","volume-title":"APA handbook of research methods in psychology, vol 2: research designs: Quantitative, qualitative, neuropsychological, and biological","author":"V Braun","year":"2012","unstructured":"Braun V, Clarke V. Thematic analysis. APA handbook of research methods in psychology, vol 2: research designs: Quantitative, qualitative, neuropsychological, and biological. Washington, DC, US: American Psychological Association; 2012. pp. 57\u201371. (APA handbooks in psychology\u00ae)."},{"issue":"3","key":"1409_CR73","doi-asserted-by":"publisher","first-page":"e0299801","DOI":"10.1371\/journal.pone.0299801","volume":"19","author":"N Henderson","year":"2024","unstructured":"Henderson N, Marris J, Woodend K. And this is the life jacket, the lifeline they\u2019ve been wanting: participant perspectives on navigating challenges and successes of prescribed safer supply. PLoS ONE. 2024;19(3):e0299801.","journal-title":"PLoS ONE"},{"key":"1409_CR74","volume-title":"Safer supply is the thing that changes everything: the role of prescribed safer supply in rebuilding trust following experiences of medical abandonment","author":"G Kolla","year":"2024","unstructured":"Kolla G, Pauly B, Henderson N, Majalahti J, Toombs K, LeMaistre J, et al. Safer supply is the thing that changes everything: the role of prescribed safer supply in rebuilding trust following experiences of medical abandonment. Canada: In Montreal; 2024."},{"issue":"2","key":"1409_CR75","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/dar.12411","volume":"36","author":"W Damon","year":"2017","unstructured":"Damon W, Small W, Anderson S, Maher L, Wood E, Kerr T, et al. Crisis\u2019 and \u2018everyday\u2019 initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug Alcohol Rev. 2017;36(2):253\u201360.","journal-title":"Drug Alcohol Rev"},{"issue":"10","key":"1409_CR76","first-page":"e443","volume":"65","author":"S Spithoff","year":"2019","unstructured":"Spithoff S, Meaney C, Urbanoski K, Harrington K, Que B, Kahan M, et al. Opioid agonist therapy during residential treatment of opioid use disorder: cohort study on access and outcomes. Can Fam Physician Med Fam Can. 2019;65(10):e443\u201352.","journal-title":"Can Fam Physician Med Fam Can"},{"issue":"1","key":"1409_CR77","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12913-020-05670-z","volume":"20","author":"CE Kendall","year":"2020","unstructured":"Kendall CE, Boucher LM, Donelle J, Martin A, Marshall Z, Boyd R, et al. Engagement in primary health care among marginalized people who use drugs in Ottawa, Canada. BMC Health Serv Res. 2020;20(1):837.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1409_CR78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1210\/jc.2004-0929","volume":"90","author":"N Bliesener","year":"2005","unstructured":"Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingm\u00fcller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1409_CR79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/1574886317666220514154931","volume":"18","author":"K Khalid","year":"2023","unstructured":"Khalid K, Anuar A, Ang WC, Jamaluddin R. Side effects of chronic methadone use in opioid addiction: A scoping review on hematological derangements. Curr Drug Saf. 2023;18(2):167\u201374.","journal-title":"Curr Drug Saf"},{"key":"1409_CR80","doi-asserted-by":"publisher","first-page":"103709","DOI":"10.1016\/j.drugpo.2022.103709","volume":"105","author":"M Selfridge","year":"2022","unstructured":"Selfridge M, Card K, Kandler T, Flanagan E, Lerhe E, Heaslip A, et al. Factors associated with 60-day adherence to safer supply opioids prescribed under British columbia\u2019s interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency. Int J Drug Policy. 2022;105:103709.","journal-title":"Int J Drug Policy"},{"issue":"S5","key":"1409_CR81","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/jia2.70038","volume":"28","author":"A Guta","year":"2025","unstructured":"Guta A, Rudzinski K, Gagnon M, Schmidt RA, Kolla G, German D, et al. From an HCV and HIV point of view, it\u2019s been remarkable: A qualitative study about using prescribed safer supply to support people who use drugs along the HIV and HCV prevention and treatment cascades in Ontario, Canada. J Int AIDS Soc. 2025;28(S5):e70038.","journal-title":"J Int AIDS Soc"},{"key":"1409_CR82","doi-asserted-by":"publisher","first-page":"102930","DOI":"10.1016\/j.drugpo.2020.102930","volume":"85","author":"S Mayer","year":"2020","unstructured":"Mayer S, Fowler A, Brohman I, Fairbairn N, Boyd J, Kerr T, et al. Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: A qualitative study of patient experiences in Vancouver, Canada. Int J Drug Policy. 2020;85:102930.","journal-title":"Int J Drug Policy"},{"key":"1409_CR83","doi-asserted-by":"crossref","unstructured":"Fraser S, Valentine K. Substance and substitution: methadone subjects in Liberal societies. Springer; 2008. p. 213.","DOI":"10.1057\/9780230582569"},{"issue":"12","key":"1409_CR84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/15265161.2017.1388868","volume":"17","author":"A Guta","year":"2017","unstructured":"Guta A, Strike CJ, Gagnon M. Changing the conversation: A critical bioethics response to the opioid crisis. Am J Bioeth AJOB. 2017;17(12):53\u20134.","journal-title":"Am J Bioeth AJOB"},{"key":"1409_CR85","doi-asserted-by":"publisher","first-page":"108918","DOI":"10.1016\/j.jsat.2022.108918","volume":"144","author":"JM Husain","year":"2023","unstructured":"Husain JM, Cromartie D, Fitzelle-Jones E, Brochier A, Borba CPC, Montalvo C. A qualitative analysis of barriers to opioid agonist treatment for racial\/ethnic minoritized populations. J Subst Abuse Treat. 2023;144:108918.","journal-title":"J Subst Abuse Treat"},{"key":"1409_CR86","doi-asserted-by":"publisher","first-page":"103815","DOI":"10.1016\/j.drugpo.2022.103815","volume":"108","author":"M Perri","year":"2022","unstructured":"Perri M, Schmidt RA, Guta A, Kaminski N, Rudzinski K, Strike C. COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services. Int J Drug Policy. 2022;108:103815.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1409_CR87","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12954-023-00893-9","volume":"20","author":"D Frank","year":"2023","unstructured":"Frank D, Elliott L, Cleland CM, Walters SM, Joudrey PJ, Russell DM, et al. As safe as possible: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids. Harm Reduct J. 2023;20(1):158.","journal-title":"Harm Reduct J"},{"issue":"8","key":"1409_CR88","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/add.14947","volume":"115","author":"M Piske","year":"2020","unstructured":"Piske M, Zhou H, Min JE, Hongdilokkul N, Pearce LA, Homayra F, et al. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction. 2020;115(8):1482\u201393.","journal-title":"Addiction"},{"key":"1409_CR89","doi-asserted-by":"crossref","unstructured":"Gomes T, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, et al. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in ontario: a population-based propensity\u2010score matched cohort study. Addiction. 2022 July;117(7):1972\u201381.","DOI":"10.1111\/add.15862"},{"key":"1409_CR90","doi-asserted-by":"publisher","unstructured":"Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R et al. Buprenorphine\/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.16954","DOI":"10.1001\/jama.2024.16954"},{"issue":"3","key":"1409_CR91","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O\u2019Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356\u201361.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1409_CR92","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addict Abingdon Engl. 2014;109(1):79\u201387.","journal-title":"Addict Abingdon Engl"},{"issue":"1","key":"1409_CR93","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13011-019-0241-2","volume":"14","author":"G Bardwell","year":"2019","unstructured":"Bardwell G, Wood E, Brar R. Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? Subst Abuse Treat Prev Policy. 2019;14(1):50.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1409_CR94","unstructured":"Howard DL. Effective Treatment of Opioid Use Disorder among African Americans. In: Effective Prevention and Treatment of Substance Use Disorders for Racial and Ethnic Minorities [Internet]. IntechOpen; 2019 [cited 2025 Apr 5]. Available from: https:\/\/www.intechopen.com\/chapters\/68923"},{"issue":"6","key":"1409_CR95","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1111\/j.1475-6773.2008.00870.x","volume":"43","author":"HA Pollack","year":"2008","unstructured":"Pollack HA, D\u2019Aunno T. Dosage patterns in methadone treatment: results from a National Survey, 1988\u20132005. Health Serv Res. 2008;43(6):2143\u201363.","journal-title":"Health Serv Res"},{"key":"1409_CR96","doi-asserted-by":"publisher","first-page":"103573","DOI":"10.1016\/j.drugpo.2021.103573","volume":"102","author":"K Corace","year":"2022","unstructured":"Corace K, Suschinsky K, Wyman J, Leece P, Cragg S, Konefal S, et al. Evaluating how has care been affected by the Ontario COVID-19 opioid agonist treatment guidance: patients\u2019 and prescribers\u2019 experiences with changes in unsupervised dosing. Int J Drug Policy. 2022;102:103573.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"1409_CR97","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2022.1271","volume":"327","author":"T Gomes","year":"2022","unstructured":"Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, et al. Association between increased dispensing of opioid agonist therapy Take-Home doses and opioid overdose and treatment interruption and discontinuation. JAMA. 2022;327(9):846\u201355.","journal-title":"JAMA"},{"key":"1409_CR98","doi-asserted-by":"publisher","first-page":"104721","DOI":"10.1016\/j.drugpo.2025.104721","volume":"137","author":"TN Rieder","year":"2025","unstructured":"Rieder TN. Ethical justifications for safe supply interventions. Int J Drug Policy. 2025;137:104721.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1409_CR99","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jama.2021.11013","volume":"326","author":"A Agnoli","year":"2021","unstructured":"Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed Long-term opioids. JAMA. 2021;326(5):411.","journal-title":"JAMA"},{"issue":"12","key":"1409_CR100","doi-asserted-by":"publisher","first-page":"e1004123","DOI":"10.1371\/journal.pmed.1004123","volume":"19","author":"MC Kennedy","year":"2022","unstructured":"Kennedy MC, Crabtree A, Nolan S, Mok WY, Cui Z, Chong M, et al. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, canada: A retrospective cohort study. PLOS Med. 2022;19(12):e1004123.","journal-title":"PLOS Med"},{"key":"1409_CR101","doi-asserted-by":"crossref","unstructured":"Shaw J, Murphy AL, Turner JP, Gardner DM, Silvius JL, Bouck Z et al. Policies for Deprescribing: An International Scan of Intended and Unintended Outcomes of Limiting Sedative-Hypnotic Use in Community-Dwelling Older Adults. Healthc Policy [Internet]. 2019 May 30 [cited 2025 Apr 5];14(4). Available from: https:\/\/www.longwoods.com\/content\/25857\/healthcare-policy\/policies-for-deprescribing-an-international-scan-of-intended-and-unintended-outcomes-of-limiting-se","DOI":"10.12927\/hcpol.2019.25857"},{"issue":"1","key":"1409_CR102","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13011-019-0220-7","volume":"14","author":"S Taha","year":"2019","unstructured":"Taha S, Maloney-Hall B, Buxton J. Lessons learned from the opioid crisis across the pillars of the Canadian drugs and substances strategy. Subst Abuse Treat Prev Policy. 2019;14(1):32.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1409_CR103","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13011-023-00525-2","volume":"18","author":"G Bardwell","year":"2023","unstructured":"Bardwell G, Bowles JM, Mansoor M, Werb D, Kerr T. Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, canada: a qualitative study. Subst Abuse Treat Prev Policy. 2023;18(1):14.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1409_CR104","doi-asserted-by":"crossref","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, canada: A qualitative study. Drug Alcohol Depend. 2020;216.","DOI":"10.1016\/j.drugalcdep.2020.108202"},{"issue":"6","key":"1409_CR105","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/09687637.2023.2283383","volume":"31","author":"C Macevicius","year":"2024","unstructured":"Macevicius C, Gudi\u00f1o P\u00e9rez D, Norton A, Kolla G, Beck-McGreevy P, Selfridge M, et al. Just have this come from their prescription pad: the medicalization of safer supply from the perspectives of health planners in BC, Canada. Drugs Educ Prev Policy. 2024;31(6):658\u201368.","journal-title":"Drugs Educ Prev Policy"},{"key":"1409_CR106","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.drugalcdep.2017.06.009","volume":"178","author":"N Krawczyk","year":"2017","unstructured":"Krawczyk N, Feder KA, Fingerhood MI, Saloner B. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a US National sample. Drug Alcohol Depend. 2017;178:512\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1409_CR107","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2021.21040381","volume":"179","author":"J Friedman","year":"2022","unstructured":"Friedman J, Beletsky L, Jordan A. Surging Racial disparities in the U.S. Overdose crisis. Am J Psychiatry. 2022;179(2):166\u20139.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1409_CR108","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.amepre.2024.12.020","volume":"68","author":"MK Smith","year":"2025","unstructured":"Smith MK, Planalp C, Bennis SL, Stately A, Nelson I, Martin J, et al. Widening Racial disparities in the U.S. Overdose epidemic. Am J Prev Med. 2025;68(4):745\u201353.","journal-title":"Am J Prev Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01409-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01409-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01409-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:03:44Z","timestamp":1773147824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01409-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01409-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was provided by all participants for data from this study to be used in journal articles, reports and presentations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The authors obtained all required ethical approvals for the work reported in this paper. The University of Toronto Research Ethics Board approved this study. Informed consent was obtained from all participants prior to their participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"51"}}